Search results for: Category

Accelerating research progress for brain cancer

Patients with rare cancers often face limited options for treatment, particularly given the fact that it is challenging to design clinical trials that enroll enough patients with these rare cancers to thoroughly test new therapies. This is very much the case for many brain cancers, which tend to be rare, deadly, and resistant to typical cancer therapies. In an effort to help counter this trend, Baylor Scott & White Research Institute (BSWRI) is actively pursuing research aimed at bringing more trial opportunities, and ultimately, potential future treatment options to patients with cancers of the brain. A notable advantage that BSWRI brings to this effort is its ability to link multiple sites across the Baylor Scott & White system under their clinical trials. In doing so, BSWRI is able to engage a more diverse population, and therefore more potentially eligible patients, across not only in the state of Texas, but neighboring states.

Read more

Lipoprotein (a): new patient-centered recommendations for evaluating the risk of heart disease

Lipoprotein (a), also known as Lp(a), has been long suspected to be an independent risk factor for cardiovascular disease (CVD). Some studies have estimated that 20% of the Caucasian U.S. population may have increased CVD risk due to elevated plasma Lp(a) levels. However, until recently, a lack of robust assays to measure Lp(a) levels has prevented scientific consensus on the nature of Lp(a)-associated risk.

Read more

Pathology preparedness and a scalable pandemic response

The 2020 COVID-19 pandemic associated with the novel SARS-CoV-2 virus has required an unprecedented mobilization of resources worldwide. One of the cornerstones to pandemic response is rapid initiation of widespread testing. To meet this need, physicians and researchers at Baylor Scott & White Research Institute were quick to establish reliable testing for SARS-CoV-2 virus, and their experience can serve as a guide for the response to future novel infectious diseases.

Read more